Published in J Clin Invest on September 15, 1998
Study of gp75 Vaccine in Patients With Stage III and IV Melanoma | NCT00034554
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
B16 as a mouse model for human melanoma. Curr Protoc Immunol (2001) 1.80
Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther (2009) 1.69
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest (2006) 1.59
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res (2006) 1.57
Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res (2007) 1.56
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med (2009) 1.47
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med (2000) 1.31
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther (2008) 1.22
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A (2001) 1.14
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res (2000) 1.12
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun (2009) 1.09
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun (2006) 1.04
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One (2010) 0.99
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine (2006) 0.99
A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine (2009) 0.92
Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection. Clin Cancer Res (2010) 0.90
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J (2011) 0.86
Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med (2004) 0.86
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res (2008) 0.86
Mechanisms of immunization against cancer using chimeric antigens. Mol Ther (2008) 0.85
Immune rejection of mouse tumors expressing mutated self. Cancer Res (2009) 0.84
Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci U S A (1999) 0.84
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol (2015) 0.81
DNA vaccination: using the patient's immune system to overcome cancer. Clin Dev Immunol (2010) 0.80
Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One (2013) 0.77
Generation and characterization of transgenic mice expressing a T-cell receptor specific for the tumour-associated antigen MDM2. Immunology (2008) 0.76
Oncolytic plasmid: A novel strategy for tumor immuno-gene therapy. Oncol Lett (2011) 0.76
A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One (2007) 0.76
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients. Oncotarget (2016) 0.75
Intraperitoneal immunotherapy: historical perspectives and modern therapy. Cancer Gene Ther (2016) 0.75
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Ann Transl Med (2016) 0.75
Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity. J Cancer Res Clin Oncol (2008) 0.75
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Cloning and expression of cDNA encoding mouse tyrosinase. Nucleic Acids Res (1986) 3.21
New paths in human cancer serology. J Exp Med (1998) 3.12
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
Cancer antigens: immune recognition of self and altered self. J Exp Med (1994) 2.97
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
Enzymatic control of pigmentation in mammals. FASEB J (1991) 2.47
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science (1994) 2.18
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Cancer Tumor antigens. Curr Opin Immunol (1997) 1.89
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother Emphasis Tumor Immunol (1996) 1.72
The role of tyrosinase in autoimmune vitiligo. Lancet (1994) 1.66
Tumour antigens. A new look for the 1990s. Nature (1994) 1.56
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35). J Exp Med (1996) 1.38
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol (1988) 1.34
Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol (1997) 1.17
Sorting and secretion of a melanosome membrane protein, gp75/TRP1. J Invest Dermatol (1997) 1.03
Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection. Int J Cancer (1995) 1.01
Anti-tyrosinase antibodies in malignant melanoma. Cancer Immunol Immunother (1996) 1.00
Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol (1997) 0.93
Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res (1997) 0.91
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg (2000) 13.24
FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell (1994) 7.66
ATR and ATRIP: partners in checkpoint signaling. Science (2001) 7.58
Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A (1980) 7.33
BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev (2000) 7.29
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell (2000) 6.70
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol (2010) 5.91
Histone-like TAFs within the PCAF histone acetylase complex. Cell (1998) 5.26
Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22
EEG coherency. I: Statistics, reference electrode, volume conduction, Laplacians, cortical imaging, and interpretation at multiple scales. Electroencephalogr Clin Neurophysiol (1997) 4.17
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum (1980) 3.87
Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell (1999) 3.47
Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell (2000) 3.44
The Flory isolated-pair hypothesis is not valid for polypeptide chains: implications for protein folding. Proc Natl Acad Sci U S A (2000) 3.39
Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology (2001) 3.35
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Identification of a translation initiation factor 3 (eIF3) core complex, conserved in yeast and mammals, that interacts with eIF5. Mol Cell Biol (1998) 2.91
Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev (2000) 2.90
The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer (1999) 2.90
Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem (2000) 2.89
A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol Cell (1999) 2.71
Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J (1998) 2.68
Community health worker performance in the management of multiple childhood illnesses: Siaya District, Kenya, 1997-2001. Am J Public Health (2001) 2.64
Rules for alpha-helix termination by glycine. Science (1994) 2.64
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Direct measurement of chlorine penetration into biofilms during disinfection. Appl Environ Microbiol (1994) 2.51
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product. J Exp Med (1990) 2.44
Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and GCN2. Mol Cell Biol (1998) 2.39
Critical role of a common transcription factor, IRF-1, in the regulation of IFN-beta and IFN-inducible genes. EMBO J (1992) 2.34
Regulation of the Bub2/Bfa1 GAP complex by Cdc5 and cell cycle checkpoints. Cell (2001) 2.33
Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med (1997) 2.31
A semiparametric empirical likelihood method for data from an outcome-dependent sampling scheme with a continuous outcome. Biometrics (2002) 2.25
Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med (2000) 2.25
Excimer laser surgery of the cornea. Am J Ophthalmol (1983) 2.22
A complete conformational map for RNA. J Mol Biol (1999) 2.16
Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med (1999) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med (1995) 2.13
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther (2010) 2.13
Protein identification using mass spectrometric information. Electrophoresis (1998) 2.11
The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol Cell (1998) 2.08
Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol (2001) 2.06
Impact of an early weighing policy on neonatal hypernatraemic dehydration and breast feeding. Arch Dis Child (2007) 2.05
Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer (1999) 2.03
Surgical management of intra-abdominal desmoid tumours. Br J Surg (2000) 2.01
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med (1989) 1.98
EEG coherency II: experimental comparisons of multiple measures. Clin Neurophysiol (1999) 1.97
Distribution of kinetochore (centromere) antigen in mammalian cell nuclei. J Cell Biol (1981) 1.97
Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92
Identification of phosphorylation sites in proteins separated by polyacrylamide gel electrophoresis. Anal Chem (1998) 1.89
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer (2001) 1.86
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci U S A (1996) 1.85
The impact of direct refinement against 13C alpha and 13C beta chemical shifts on protein structure determination by NMR. J Magn Reson B (1995) 1.84
Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med (1996) 1.83
Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol (2000) 1.83
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. Proc Natl Acad Sci U S A (1994) 1.81
Direct imaging of transient molecular structures with ultrafast diffraction. Science (2001) 1.81
Dermatofibrosarcoma protuberans: A clinicopathologic analysis of patients treated and followed at a single institution. Cancer (2000) 1.78
Prognostic factors associated with long-term survival for retroperitoneal sarcoma: implications for management. J Clin Oncol (1997) 1.77
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75. J Cell Biol (1995) 1.76
Core needle biopsy for diagnosis of extremity soft tissue sarcoma. Ann Surg Oncol (1997) 1.75
Generation of human monoclonal antibodies reactive with cellular antigens. Proc Natl Acad Sci U S A (1983) 1.71
Investigating neural correlates of conscious perception by frequency-tagged neuromagnetic responses. Proc Natl Acad Sci U S A (1998) 1.68
A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR. EMBO J (2000) 1.68
Fragmentation of phosphopeptides in an ion trap mass spectrometer. J Am Soc Mass Spectrom (1998) 1.67
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
The USA-derived transcriptional coactivator PC2 is a submodule of TRAP/SMCC and acts synergistically with other PCs. Mol Cell (2000) 1.65
Modeling unfolded states of proteins and peptides. II. Backbone solvent accessibility. Biochemistry (1997) 1.64
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Platelet integrin alpha(IIb)beta(3): activation mechanisms. J Thromb Haemost (2007) 1.63
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine (2005) 1.59
Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol (2001) 1.59
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. Proc Natl Acad Sci U S A (1982) 1.59
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58
IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity (2001) 1.56
CD4+ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. J Exp Med (1998) 1.56
Use of a mydriatic cocktail with a wick for preoperative mydriasis in cataract surgery: a prospective randomised controlled trial. Eye (Lond) (2009) 1.55
Role of IFN-gamma in lethal and nonlethal malaria in susceptible and resistant murine hosts. J Immunol (1989) 1.54
Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer (1993) 1.52
Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma. Oncogene (2011) 1.50
Epidemiology and symptom profile of gastroesophageal reflux in the Indian population: report of the Indian Society of Gastroenterology Task Force. Indian J Gastroenterol (2011) 1.49
Phosphorylation of the human La antigen on serine 366 can regulate recycling of RNA polymerase III transcription complexes. Cell (1997) 1.49
A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci U S A (2000) 1.49
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma. J Exp Med (1983) 1.48
Oculocutaneous manifestations in xeroderma pigmentosa. Br J Ophthalmol (1994) 1.48